These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 11051272)
1. Correspondence re: M. Fanciulli et al., Energy metabolism of human LoVo colon carcinoma cells: correlation to drug resistance and influence fo lonidamine. Clin. Cancer Res., 6: 1590-1597, 2000. Kaplan O Clin Cancer Res; 2000 Oct; 6(10):4166-7. PubMed ID: 11051272 [No Abstract] [Full Text] [Related]
2. Energy metabolism of human LoVo colon carcinoma cells: correlation to drug resistance and influence of lonidamine. Fanciulli M; Bruno T; Giovannelli A; Gentile FP; Di Padova M; Rubiu O; Floridi A Clin Cancer Res; 2000 Apr; 6(4):1590-7. PubMed ID: 10778993 [TBL] [Abstract][Full Text] [Related]
3. [Treatment and post-treatment with lonidamine in human colon carcinoma HT-29 cell line]. Fuchs AG Medicina (B Aires); 2008; 68(1):13-22. PubMed ID: 18416315 [TBL] [Abstract][Full Text] [Related]
4. Effect of the antitumor drug lonidamine on glucose metabolism of adriamycin-sensitive and -resistant human breast cancer cells. Fanciulli M; Valentini A; Bruno T; Citro G; Zupi G; Floridi A Oncol Res; 1996; 8(3):111-20. PubMed ID: 8823807 [TBL] [Abstract][Full Text] [Related]
5. [Targeting the gene of glucose metabolism for the treatment of advanced gliomas]. Oudard S; Miccoli L; Dutrillaux B; Poupon MF Bull Cancer; 1998 Jul; 85(7):622-6. PubMed ID: 9752269 [TBL] [Abstract][Full Text] [Related]
6. Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells. Floridi A; Paggi MG; D'Atri S; De Martino C; Marcante ML; Silvestrini B; Caputo A Cancer Res; 1981 Nov; 41(11 Pt 1):4661-6. PubMed ID: 7306982 [TBL] [Abstract][Full Text] [Related]
7. Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells. Floridi A; Paggi MG; Marcante ML; Silvestrini B; Caputo A; De Martino C J Natl Cancer Inst; 1981 Mar; 66(3):497-9. PubMed ID: 6937706 [TBL] [Abstract][Full Text] [Related]
8. Re-programming tumour cell metabolism to treat cancer: no lone target for lonidamine. Bhutia YD; Babu E; Ganapathy V Biochem J; 2016 Jun; 473(11):1503-6. PubMed ID: 27234586 [TBL] [Abstract][Full Text] [Related]
9. Glucose metabolism in adriamycin-sensitive and -resistant LoVo human colon carcinoma cells. Fanciulli M; Bruno T; Castiglione S; Del Carlo C; Paggi MG; Floridi A Oncol Res; 1993; 5(9):357-62. PubMed ID: 8038456 [TBL] [Abstract][Full Text] [Related]
11. [Relationship between multidrug resistance in human colon carcinoma LoVo/Adr cell line and intracellular calcium ion concentration]. Ma Q; Zhang ZS; Zhang YL; Lai ZS Ai Zheng; 2002 Aug; 21(8):846-9. PubMed ID: 12478890 [TBL] [Abstract][Full Text] [Related]
12. A search for multidrug resistance modulators: the effects of retinoids in human colon carcinoma cells. Bartolini G; Orlandi M; Papi A; Ammar K; Guerra F; Ferreri AM; Rocchi P In Vivo; 2006; 20(6A):729-33. PubMed ID: 17203756 [TBL] [Abstract][Full Text] [Related]
13. Correspondence re: A. Kumar et al., cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma. Cancer Res., 61: 7552-7555, 2001. Garattini E; Gianni' M; Terao M Cancer Res; 2002 Apr; 62(7):2192-3; author reply 2193-4. PubMed ID: 11929843 [No Abstract] [Full Text] [Related]
14. Effect of pO2 on antitumor drug cytotoxicity on MDR and non-MDR variants selected from the LoVo metastatic colon carcinoma cell line. Lelong-Rebel I; Brisson C; Fabre M; Bergerat JP; Rebel G Anticancer Res; 2008; 28(1A):55-68. PubMed ID: 18383825 [TBL] [Abstract][Full Text] [Related]
15. Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary re: A. N. Mohamed et al., The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin. Cancer Res., 9: 1333-1337, 2003. Marcucci G; Perrotti D; Caligiuri MA Clin Cancer Res; 2003 Apr; 9(4):1248-52. PubMed ID: 12684391 [No Abstract] [Full Text] [Related]
16. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo. O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895 [TBL] [Abstract][Full Text] [Related]
17. Effect of lonidamine on human malignant gliomas: biochemical studies. Paggi MG; Carapella CM; Fanciulli M; Del Carlo C; Giorno S; Zupi G; Silvestrini B; Caputo A; Floridi A J Neurooncol; 1988 Nov; 6(3):203-9. PubMed ID: 3225640 [TBL] [Abstract][Full Text] [Related]
18. To arrest or not to G(2)-M Cell-cycle arrest : commentary re: A. K. Tyagi et al., Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G(2)-M arrest, and apoptosis. Clin. cancer res., 8: 3512-3519, 2002. DiPaola RS Clin Cancer Res; 2002 Nov; 8(11):3311-4. PubMed ID: 12429616 [No Abstract] [Full Text] [Related]
19. Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Bender FC; Reymond MA; Bron C; Quest AF Cancer Res; 2000 Oct; 60(20):5870-8. PubMed ID: 11059785 [TBL] [Abstract][Full Text] [Related]
20. Identification of proteins associated to multi-drug resistance in LoVo human colon cancer cells. Visentin M; Simula MP; Sartor F; Petrucco A; De Re V; Toffoli G Int J Oncol; 2009 May; 34(5):1281-9. PubMed ID: 19360340 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]